Ipilimumab ELISA Assay Kit

$1,860.00

The Ipilimumab ELISA Assay Kit is intended as an analytical tool for the quantitative determination of Ipilimumab in serum, plasma, and cell supernatant.

SKU: KBI1025 Category:

Ipilimumab ELISA Assay Kit

The Ipilimumab ELISA Assay Kit is For Research Use Only

Size: 12×8 wells
Sensitivity: < 10 ng/mL
Standard Range: 10-640 ng/ml
Incubation Time: 2.5 hours
Sample Type: Serum, Plasma, Cell Culture Supernatants
Sample Size: 100 µL
Alternative Name: Yervoy


Assay Principle

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Ipilimumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Ipilimumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Ipilimumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to mircrowells and color develops proportionally to the amount of Ipilimumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450nm.


Sample Preparation and Storage:
Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If samples are to be used for several assays, initially aliquot samples and keep at – 20°C. For Cell Culture Supernatant – If necessary, centrifuge to remove debris prior to analysis. Samples can be stored at -20°C or -80⁰C. Avoid repeated freeze-thaw cycles.


Related Products to Ipilimumab ELISA

Anti-Ipilimumab Yervoy ELISA Assay
Denosumab (Prolia) ELISA Kit
Atezolizumab (Tecentriq) ELISA

Additional Information

Assay Background


Ipilimumab (trade name Yervoy) is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this desctruction. Ipilimumab turns off this inhibitiory mechanism and allows CTLs to function.

Documents

Product Documents


Product Citations